2019
Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection
O'Donnell MR, Padayatchi N, Daftary A, Orrell C, Dooley KE, Amico K, Friedland G. Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection. The Lancet HIV 2019, 6: e201-e204. PMID: 30846058, PMCID: PMC7155388, DOI: 10.1016/s2352-3018(19)30035-9.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisBedaquiline treatmentTuberculosis-HIVLow antiretroviral therapy adherencePotent new therapyAntiretroviral therapy initiationAntiretroviral therapy adherenceEfavirenz-containing regimensFixed-dose combinationAntiretroviral therapy switchMiddle-income settingsDaily nevirapineAdherence supportAntiretroviral resistanceAntiretroviral therapyHIV patientsTherapy initiationViral failureTherapy switchImproved survivalTherapy adherenceDrug interactionsNew therapiesHIVBedaquiline
2018
Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa
Bionghi N, Daftary A, Maharaj B, Msibi Z, Amico K, Friedland G, Orrell C, Padayatchi N, O’Donnell M. Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa. BMC Infectious Diseases 2018, 18: 171. PMID: 29642874, PMCID: PMC5896111, DOI: 10.1186/s12879-018-3080-2.Peer-Reviewed Original ResearchConceptsAnti-retroviral therapySeven-day recallPill countMedication adherenceWisepill deviceTreatment regimensTB/HIV co-infected patientsHIV co-infected adultsHIV co-infected patientsDrug-resistant tuberculosis treatmentCo-infected adultsCo-infected patientsDR-TB treatmentPilot study patientsWeekly pill countsComplex treatment regimensElectronic pill boxesLevel of adherenceTB regimensAdherence supportAntiretroviral therapyHIV patientsStudy patientsMethodsEligible patientsNew antimycobacterial drugs
2009
Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community
Shenoi S, Heysell S, Moll A, Friedland G. Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Current Opinion In Infectious Diseases 2009, 22: 11-17. PMID: 19532076, PMCID: PMC3013226, DOI: 10.1097/qco.0b013e3283210020.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisHIV patientsHIV communityIntegration of tuberculosisIndependent risk factorCourse of treatmentCommunity-based treatmentHIV careNew rapid diagnosticsRisk factorsClinical careNegative individualsTuberculosisPatientsMultidrugRapid diagnosticsCareTreatmentSusceptibility informationMorbidityHIVInfectionMortalityPhysicians
1999
Stavudine Resistance: An Update on Susceptibility following Prolonged Therapy
Lin P, González C, Griffith B, Friedland G, Calvez V, Ferchal F, Schinazi R, Shepp D, Ashraf A, Wainberg M, Soriano V, Mellors J, Colonno R. Stavudine Resistance: An Update on Susceptibility following Prolonged Therapy. Antiviral Therapy 1999, 4: 21-28. PMID: 10682125, DOI: 10.1177/135965359900400103.Peer-Reviewed Original ResearchConceptsPost-treatment isolatesStavudine resistanceStavudine therapyFirst-line combination therapyAmino acid changesUse of stavudineMonths of treatmentClinical HIV-1HIV-1 strainsNucleoside analoguesAcid changesProlonged therapyHIV patientsConsistent amino acid changesCombination therapyMulti-resistant phenotypeHIV-1Lower incidenceReverse transcriptase geneClinical isolatesTherapyDrug sensitivityPatientsTranscriptase geneCurrent report